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ABSTRACT Pharmacogenetics and pharmacogenomics show great potential for developing individual
treatment modalities to achieve optimal therapy effectiveness. Economic analyses are performed to
determine whether pharmacogenetic screening strategies provide good value for money. The current
review provides an update of published economic studies. Economic analyses of pharmacogenetic
screening programs published between 2000 and July 2010 were included in the review. Information was
extracted on research area, genetic information, type of economic analysis, key aspects of adherence to
economic guidelines, costs and commercial availability of genetic tests, and the role of the funding party.
A total of 42 economic studies on pharmacogenetic screening strategies were included. Over time, more
cost-utility analyses were performed, longer time windows were employed, and more extensive sensitivity
analyses were conducted. Considerable differences in costs of screening tests for the same polymorphism
were found, which often, but not always, had a large influence on the costs of screening strategies. Most
studies were conducted from an academic or hospital perspective without direct links to pharmaceutical
or diagnostic manufacturers. The quality of economic analyses of pharmacogenetic screening programs
has improved over time. However, input variables are not always clearly described. In particular,
substantial variation exists in the reported costs of the pharmacogenetic tests. Often these test costs are
considered a major cost driver and could therefore be of particular importance for the interpretation of
cost-effectiveness results. Furthermore, the economic studies seem to be conducted to increase awareness
of possibilities and perspectives of genetic testing rather than to influence policy decisions on
reimbursement. Drug Dev Res 71:492–501, 2010. r 2010 Wiley-Liss, Inc.
Key words: economics; pharmacogenetics; pharmacogenomics; literature review
INTRODUCTION
Pharmacogenetics and pharmacogenomics are the
disciplines that study the influence of genetic and
genomic variations on patients’ response to drug
treatment. In particular, using pharmacogenetics and
pharmacogenomics, individual treatment modalities can
be developed to achieve optimal therapy effectiveness, in
terms of both increased treatment efficacy and improved
treatment persistence due to minimization of adverse
events [Farrall and Morris, 2005; Swen et al., 2007]. The
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often used interchangeably. Some prefer to distinguish
them in that pharmacogenetics covers only single genes,
whereas pharmacogenomics implies the study of several
genes; others define pharmacogenomics to imply genetic
studies also including transcriptomic (mRNA) or pro-
teomic information [FDA, 2006; Goldstein et al., 2003].
Over the past few decades, experimental and epidemio-
logical studies have investigated a multitude of pharma-
cogenetic and pharmacogenomic treatment strategies.
Although the viability of some of these strategies is
conditional on unknown factors [Costa-Scharplatz et al.,
2007; Patrick et al., 2009] or even hypothetical [Vegter
et al., 2009; Welton et al., 2008] in nature, a growing
number of pharmacogenetic tests are indeed becoming
commercially available and are used increasingly in
clinical practice [Swen et al., 2007]. Generally speaking,
these tests can be divided into two principally distinct
areas: (1) pharmacodynamic based pharmacogenetics,
which aim to target specific diseases or disease subtypes;
and (2) pharmacokinetic based tests, commonly when
referring to genes influencing drug metabolism [Hopkins
et al., 2006]. Pharmacokinetic based testing before
treatment initiation seems to be one of the most
promising applications of pharmacogenetics. Pharmaco-
genetic testing prior to treatment initiation can be
helpful to predict treatment response and assess the risks
for adverse drug reactions.
Notwithstanding the clinical relevance of pharma-
cogenetics, economic analyses are being performed to
determine whether individual pharmacogenetic tests
provide good value for money. Different types of
economic evaluations can be distinguished: (1) cost
minimization analysis (CMA), in which only the costs of
two or more treatment strategies are compared (and the
health benefits are assumed to be identical); (2) cost
effectiveness analysis (CEA), in which health benefits
are also taken into account, measured in natural units
(such as life years saved); and (3) cost utility analysis
(CUA), which combines health outcomes from CEA
with measurements of patient wellbeing (utility) such as
quality-adjusted life-years (QALYs). In a CUA, outcomes
can be compared across different disease fields, in
contrast to CEA, which are often confined to their
respective disease areas. A fourth type of economic
analysis, the cost-benefit analysis (CBA), in which both
benefits and costs are expressed in monetary terms, is
seldom performed and is not recommended in guide-
lines for conducting economic analyses [International
Society for Pharmacoeconomics and Outcomes, 2010;
Walley and Haycox, 1997].
In 2008, we published a systematic review on
economic evaluations of pharmacogenetic screening
programs [Vegter et al., 2008]. Twenty economic
analyses, published up until 2007, were included in this
previous review, focusing on the different disease
fields and the level of adherence to international
economic guidelines [International Society for Pharma-
coeconomics and Outcomes, 2010]. Many economic
evaluations reported an acceptable cost effectiveness or
even dominating (cost savings as well as clinical benefits)
outcome for pharmacogenetic screen-and-treat strate-
gies. However, we expressed concerns regarding the
consistency and overall quality of the selected economic
analyses. Several other literature reviews on the
economics of pharmacogenetic screening programs have
previously been published. These studies give an
overview of studies conducted and describe the role
and interpretation of cost effectiveness in the field of
pharmacogenetics and pharmacogenomics [Dervieux
and Bala, 2006; Flowers and Veenstra, 2004; Phillips
and Van Bebber, 2004].
The purpose of the current study was to perform
an update of newly published economic studies to
describe the status quo of cost-effectiveness analysis for
pharmacogenetic and pharmacogenomic testing.
METHODS
Literature searches were performed using PubMed.
Studies published between 2000 and July 2010 were
collected. MESH terms used were ‘‘economics,’’ ‘‘phar-
macogenetics,’’ ‘‘cost-effectiveness analysis,’’ ‘‘genotype,’’
and ‘‘economic outcomes,’’ in different combinations.
Studies were included if they met the following require-
ments: (1) articles were peer-reviewed and available in
full text; (2) an economic analysis was performed on a
genetic screening method, screening either human or
viral genome; and (3) the genetic or genomic variations
were shown, or were at least assumed, to influence drug
efficacy or drug safety. Editorials, reviews, and other
nonoriginal research articles were excluded. All studies
were searched by two reviewers (SV and EJ).
The following data were extracted from the
included articles: area of disease or patient population;
gene(s) analyzed by the pharmacogenetic test; pharma-
ceutical compound influenced by the genetic variation;
type of economic analysis; several key aspects of
adherence to economic guidelines (sensitivity analysis,
time window and discounting [Vegter et al., 2008];
outcome measurements; and outcome. The costs and
commercial status of the pharmacogenetic tests were
extracted and compared. Furthermore, we screened all
selected papers for the role of the funding party (e.g.,
academic, pharmaceutical industry, or other institutes
involved with drug development or genetic tests) to
value the authors’ publishing aim. Overall, these
aspects do not only cover basic information on the
economic analyses but also on the level of adherence
to economic guidelines [International Society for
493ECONOMICS OF PHARMACOGENETIC SCREENING
Drug Dev. Res.
Pharmacoeconomics and Outcomes, 2010] as well as
practicalities and the scope or incentives for conduct-
ing these analyses.
RESULTS
Number and Type of Studies
A total of 42 economic studies on pharmacoge-
netic screen-and-treat strategies were included, more
than twice the number of studies (n5 20) included in
our previous review [Vegter et al., 2008]. The number
of studies published in the second half of the decade
(n5 30) was almost three times that of the first half of
the decade (n5 12); only two studies were published in
2000, compared with nine studies in 2009. An overview
of all the studies is shown in Table 1. There was a clear
shift in the type of economic analysis performed over
time. In particular, whereas a mix of CMA, CEA, and
CUA studies were performed before 2008, most
studies published after 2007 were CEA or CUA,
reporting clinical outcomes in life-years gained and
QALYs gained, respectively.
Topics
Cost-effectiveness analyses of thiopurine methyl-
transferase (TPMT) polymorphism screening was
popular before 2008, being the topic of seven (27%)
out of the 27 studies included in a previous systematic
review [Vegter et al., 2008]. Interestingly, none of the
economic studies published after 2007 examined
pharmacogenetic testing of this gene. On the other
hand, the number of studies examining CYP2C9 or
VKORC1 testing in relation to warfarin treatment
increased markedly from only 2 (8%) out of 27 studies
published before 2008 [Vegter et al., 2008], to four
(25%) out of 16 studies published after 2007. All
economic studies on pharmacogenetic tests are sum-
marized in Table 1.
Outcome
Most studies were not unambiguous in giving
positive or negative conclusions on the cost effective-
ness of the genetic screening program. In fact, two
studies mainly focused on the circumstances required
for a pharmacogenetic test to be cost effective with
different levels of clinical effectiveness [Patrick et al.,
2009; Vegter et al., 2009]. Other studies include the
availability of resources and practical possibilities to
calculate ‘‘conditional’’ cost-effectiveness outcomes. In
an example on CYP2C9 and VKORC1 screening, the
authors assumed that most institutions cannot perform
genotype testing in their own laboratories, which
results in a high cost effectiveness of US$171,800 per
QALY gained [Eckman et al., 2009]. However, with in-
hospital genotyping, the cost effectiveness was much
more favorable at US$51,000 per QALY gained [Eckman
et al., 2009]. In general, the cost-effectiveness out-
comes of CYP2C9 and VKORC1 genotyping are often
high, whereas CYP2C19 and TPMT testing are often
reported to result in cost-saving strategies.
Cost of Genetic Tests
The costs of genetic testing used in the economic
analyses are also shown in Table 1. Considerable
differences in screening tests for the same polymorph-
isms were found. These differences are expected to be
caused by estimates including only material costs
versus estimates with including personnel costs, such
as in ACE (I/D) genotyping, which varied between h7
(Netherlands, 2002) [Maitland-van der Zee et al., 2004]
and h50 (Netherlands, 2005/2008) [Costa-Scharplatz
et al., 2007; Vegter et al., 2009]. Other differences
might be caused by between country differences or
costing year, such as in HER-2 testing, in which the
assumed screening costs varied between h283 (France,
2002) [Morelle et al., 2006] and h548 (Sweden, 2005)
[Lidgren et al., 2008a,b]. Commercial available tests
are expected to have fixed prices rather than large
variation in costs. Still, some differences in the base
case estimate of screening costs were observed among
studies that both were based on commercially available
tests, were conducted from the same study perspective
and in the same country and year, for example of
CYP2C9 and VKORC1 testing, varying between
US$175 (USA, 2007) [Meckley et al., 2010] and
US$575 (USA, 2007) [Patrick et al., 2009]. The costs
of genetic screening tests were often, but not always,
explored in sensitivity analyses.
Sensitivity Analyses
Economic evaluations invariably have to deal with
some degree of uncertainty in their analyses. This is
especially true for pharmacogenetic screening pro-
grams, which are often not yet (commonly) implemen-
ted in clinical practice or might even be hypothetical in
nature. Therefore, sensitivity analyses are invaluable to
determine the influence of key parameters and the
preconditions for cost effectiveness of the screening
strategy. Furthermore, probabilistic sensitivity analyses
are performed to determine the range of cost effec-
tiveness and the probability of a screening strategy of
being cost effective. All studies included in this review
performed some form of sensitivity analysis. Before
2008, most of these were limited to deterministic
sensitivity analyses (in which only one variable is varied
at a time). In contrast to this, almost all (except one)
studies that were published after 2007 performed
probabilistic sensitivity analyses, a method that allows
for assessing more of the inherent uncertainty associated
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with genetic screening programs. As discussed above,
we identified large variation in the costs of the genetic
screening test. In the case of HER-2 testing and
CYP2C9 and VKORC1 testing, sensitivity analyses
demonstrated that the uncertainty around the costs of
the pharmacogenomic test showed high influence on the
calculated cost effectiveness [Eckman et al., 2009;
Meckley et al., 2010; Morelle et al., 2006; Patrick
et al., 2009; You et al., 2009]. Therefore, economic
outcomes for pharmacogenetic tests could be (highly)
sensitive for these cost estimates. However, for ACE
(I/D) genotyping and genotypic antiretroviral resistance
testing (GART), the influence of screening costs was
limited [Maitland-van der Zee et al., 2004; Sax et al.,
2005; Vegter et al., 2009; Weinstein et al., 2001]. Here,
the costs of the tests are not a direct total cost driver.
Time Window and Discounting
Guidelines state that the length of any economic
evaluation should be long enough to capture all
differential effects of compared interventions. Since
genetic variations occur at birth and do not change
during life, with the exception of cancer cells,
evaluations of genetic screening programs can be
expected to employ a lifelong time window or at least
as long as treatment effects are expected to last. Most
studies published before 2008 employed a time
window of 12 months; only five of the 20 paper
included in our previous review employed a life-time
horizon [Vegter et al., 2008]. In contrast, most studies
published after 2007 employed a lifetime horizon,
although this might be as short as 24 months as in the
case of metastatic colorectal cancer [Gold et al., 2009].
Time horizons other than 1 year can be appropriate
if incidental effects occur that do not last for more than
a certain specified time period. Discounting—the
method to correct for time preferences that occur in
relation to gains and losses—was applied in all studies
[Drummond et al., 2005].
Role of Funding
Most studies included were not (directly) funded
by pharmaceutical companies or pharmacogenetic test
suppliers and were written from an academic or
hospital perspective rather than a commercial perspec-
tive. Only two studies on trastuzumab treatment of
HER-2-positive breast cancer [Lidgren et al., 2008a,b]
were found to be directly funded by a pharmaceutical
company. The company involved produces the drug
and owns the company that supplies diagnostic
instruments for HER-2 screening. As another example,
in a study on CYP2D6 screening before antipsychotic
therapy [Chou et al., 2000], 6 of the 11 authors were
employed at a company that supplies genetic analysis
technologies.
DISCUSSION
The previously reported increase in good econo-
mic practice in the evaluation of pharmacogenetic and
genomic screening programs [Vegter et al., 2008],
further improved the last years. After 2007, almost
all economic studies included in the current review
were CEA and CUA studies, both recommended for
economic analysis [International Society for Pharmaco-
economics and Outcomes, 2010]. Over the years, more
elaborate and robust sensitivity analyses were per-
formed, with probabilistic sensitivity analyses also
becoming the standard in the field of pharmaco-
genetics. Applied time horizons of almost all studies
were lifetime and future costs and health effects were
discounted at appropriate rates.
In addition to an improvement in the quality of
economic analysis, also a natural change in the topics of
research was identified. In particular, no new analyses
on TMPT testing for azathioprine therapy were
published after 2008. This may be attributable to
previously reported favorable health economic out-
comes for such TPMT testing. Health economic
analyses recently focused on different and more novel
pharmacogenetic areas, such as CYP polymorphisms.
Indeed, an increasing number of studies examined
polymorphisms involved in the functioning of cyto-
chrome P-450 enzymes, such as CYP2C9 tests for
genetic-guided warfarin therapy. An explanation for
this may be that in 2007, the US Food and Drug
Authorization (FDA) updated the warfarin label,
mentioning use of genetic testing before starting
warfarin therapy [FDA, 2007]. This may have
prompted health economists to explore the value of
genetic testing. Interestingly, economic studies in this
field generally showed unfavorable value for money of
CYP2C9 screening despite the FDA update. This
underlines the importance of cost-effectiveness studies
in pharmacogenetic screening programs, which should
always be considered prior to clinical implementation
in addition to clinical evidence.
We reported that the cost-effectiveness outcomes
of CYP2C9 and VKORC1 genotyping are high whereas
CYP2C19 and TPMT testing results in cost-saving
strategies. The CYP2C9 en VKORC1 polymorphisms
explain between 35% and 55% of variability in warfarin
dose requirements [Meckley et al., 2008; Sconce et al.,
2005]. Despite this, the clinical evidence that genetic
dosing can reduce bleeding events and improve drug
efficacy is limited and the projected benefits are
small [Anderson et al., 2007]. Furthermore, reducing
warfarin doses based on genetic information might also
498 VEGTER ET AL.
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have deleterious effects by increasing the risk of
thromboembolic events [Meckley et al., 2010], which
are more severe than bleeding events. This might
explain the unfavorable cost effectiveness of this type
of genetic dosing. In contrast, the clinical benefits
of CYP2C19 screening, used for genetic dosing of
Helicobacter pylori eradiction treatment, are large,
screening is inexpensive and there is no increased risk
for adverse events with genetic dosing. Similarly,
TPMT screening, used for genetic dosing of immuno-
modulating agents, is assumed to have large clinical
benefits, even preventing cases of life-threatening
leukopenia. These clinical benefits however were based
on retrospective data or even expert opinion; the true
cost effectiveness of TPMT screening should be
evaluated based on more robust clinical and economic
evidence [Payne et al., 2009].
Despite the increasing quality of economic analyses
in this field, the practical implications of pharmaco-
genetic testing remain unclear in some studies included
for this review. There are large variations in the
estimated costs of (conducting) genetic screening tests,
which can partly but not fully be explained by variations
in the cost categories included, country of origin, and
commercialization of the screening tests. An important
additional factor is that screening costs often were based
on catalogue prices, whereas negotiated prices might be
substantially lower [Morelle et al., 2006], especially
when modeling a large-scale implementation of a genetic
screening program. These findings underline the
importance of determining the correct price for genetic
screening procedures. In some studies, the cost of the
screening test was in fact a main determinant for valuing
the intervention as cost effective or not. Therefore, it is
important to state here that sensitivity analyses should be
performed to determine the influence of all estimated
and relevant input variables on the economic outcome.
Surprisingly, for most included economic studies
on pharmacogenetic and pharmacogenomic screening
programs, no direct link with commercial sponsors was
identified. This is in contrast to economic analyses for
other healthcare interventions [Bell et al., 2006]. Most
studies were conducted from an academic or hospital
perspective without direct links with pharmaceutical
and/or diagnostic industries. This finding could indicate
that cost-effectiveness studies in the field of pharmaco-
genetics and pharmacogenomics are, at least currently,
more driven by academic interest rather than commer-
cial interests. This could be attribtutable to the limited
or less strict procedures for policy decisions (e.g.,
reimbursement) on such diagnostic tests compared
with existing procedures for drugs.
In conclusion, the quality of economic analyses
of pharmacogenetic and pharmacogenomic screening
programs improved over time. However, input vari-
ables are not always clearly described. In particular,
substantial variation exists in the costs of the pharmaco-
genetic tests that are not always fixed or estimated
consistently. Often these test costs are considered as
the major cost driver and could therefore be of
particular importance for the interpretation of cost-
effectiveness results. Furthermore, the currently pub-
lished economic studies seem to be conducted to
increase awareness of possibilities and perspectives of
genetic testing rather than to influence policy decisions
on reimbursement. Because economic outcomes are of
growing importance for implementation of health care
programs, it is highly desirable to further explore ways
to further improve the quality of cost-effectiveness
analysis for genetic tests and to give guidance to health
care decision makers.
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